Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A.
Karen L ReckampMary W RedmanKonstantin H DragnevKatherine MinichielloLiza C VillaruzBryan FallerTareq Al BaghdadiSusan HinesLeah EverhartLouise HighleymanVassiliki PapadimitrakopoulouJoel W NealSaiama N WaqarJyoti D PatelJhanelle E GrayDavid R GandaraKaren KellyRoy S HerbstPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
This randomized phase II trial demonstrated significantly improved OS with RP compared with SOC in patients with advanced NSCLC previously treated with ICI and chemotherapy. The safety was consistent with known toxicities of both drugs. These data warrant further evaluation.
Keyphrases
- advanced non small cell lung cancer
- phase ii
- open label
- placebo controlled
- clinical trial
- epidermal growth factor receptor
- double blind
- phase iii
- healthcare
- palliative care
- study protocol
- small cell lung cancer
- quality improvement
- big data
- tyrosine kinase
- locally advanced
- newly diagnosed
- electronic health record
- squamous cell carcinoma
- machine learning
- artificial intelligence
- deep learning
- radiation therapy
- affordable care act
- data analysis